Bernard G Combe (B Combe, Bernard Combe)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 31

Top Venues

RMD open

Rheumatology and therapy

Rheumatology (Oxford, England)

Annals of the rheumatic diseases

University of Montpellier and CHU montpellier

University of Montpellier (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Montpellier and CHU montpellier

France

Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments :: Rheumatology

Education History

University of Montpellier

France

PHD

Publications

Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Rempenault Claire, Cédric Lukas, Léa Tardivon, Claire Immediato Daien, Bernard G Combe, Philippe Guilpain, Jacques Morel
Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease. RMD open 10 (1) (2024)
Gaël Mouterde, Cédric Lukas, Nathalie Filippi, Gregory Marin, Nicolas Molinari, Bernard G Combe, Jacques Morel
Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study. RMD open 10 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Rempenault Claire, Cédric Lukas, Léa Tardivon, Claire Immediato Daien, Bernard G Combe, Philippe Guilpain, Jacques Morel
Risk of severe infection associated with immunoglobulin deficiency under rituximab therapy in immune-mediated inflammatory disease. RMD open 10 (1) (2024)
Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Anna Moltó, Chris Serrand, Sandrine Alonso, Francis Berenbaum, Pascal Claudepierre, Bernard G Combe, Laure Gossec, Adeline Ruyssen-Witrand, Alain Saraux, Daniel Wendling, Thierry Lequerre, Maxime Dougados
Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort. RMD open 10 (3) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Josef S Smolen, Robert B M Landewe, Désirée Mfm van der Heijde, Alexandre Sepriano, Oliver M FitzGerald, Mikkel Østergaard, Joanne Homik, Ori Elkayam, J Carter Throne, Margaret J Larché, Gianfranco Ferraccioli, Marina Backhaus, Gilles Boire, Bernard G Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi Sinigaglia, Alain G Cantagrel, Cornelia F Allaart, Cheryl C M Barnabe, Clifton O Bingham, Dirkjan van Schaardenburg, Hilde Berner Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P Maksymowych
Stricter treat-to-target in RA does not result in less radiographic progression: a longitudinal analysis in RA BIODAM. Rheumatology (Oxford, England) (2023)
Bernard G Combe, Yoshiya Tanaka, Maya H Buch, Peter Nash, Gerd R Burmester, Alan J Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K Hendrikx, Robert B M Landewé, Daniel Aletaha
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study. Rheumatology and therapy (2023)
Alexandre Sepriano, Bastiaan van Dijk, Josef S Smolen, Annette H M van der Helm van Mil, Bernard G Combe, Dirkjan van Schaardenburg, Maarten P T de Wit, Alison Kent, Elsa Mateus, Robert B M Landewe
Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts. RMD open 9 (4) (2023)
Patrick Durez, Bernard G Combe
Should we stop methotrexate or not for vaccination? RMD open 9 (2) (2023)
Bernard G Combe, Yoshiya Tanaka, Maya H Buch, Peter Nash, Gerd R Burmester, Alan J Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K Hendrikx, Robert B M Landewé, Daniel Aletaha
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study. Rheumatology and therapy (2023)
Bernard G Combe, Robin Besuyen, Antonio Gómez-Centeno, Tsukasa Matsubara, Juan José Sancho Jimenez, Zhaoyu Yin, Maya H Buch
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatology and therapy (2022)
James Martin Gwinnutt, Katherine Jones, Kimmie L Hyrich, Mark Lunt, Bernard G Combe, Nathalie Rincheval, Adeline Ruyssen-Witrand, Bruno Fautrel, Daniel Frederick McWilliams, David A Walsh, Elena Nikiphorou, Patrick D W Kiely, Adam Young, Jacqueline R Chipping, Alexander J MacGregor, Suzanne M M Verstappen
Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. Rheumatology (Oxford, England) 61 (12) (2022)
Bernard G Combe, Yoshiya Tanaka, Maya H Buch, Peter Nash, Gerd R Burmester, Alan J Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K Hendrikx, Robert B M Landewé, Daniel Aletaha
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study. Rheumatology and therapy (2022)
Charlotte Hua, Frank Buttgereit, Bernard G Combe
Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD open 6 (1) (2021)
Bernard G Combe, Alan Kivitz, Yoshiya Tanaka, Désirée Mfm van der Heijde, J Abraham Simon, Herbert S B Baraf, Uma Kumar, Franziska Matzkies, Beatrix Bartok, Lei Ye, Ying Guo, Chantal Tasset, John S Sundy, Angelika Jahreis, Mark C Genovese, Neelufar Mozaffarian, Robert B M Landewe, Sang-Cheol Bae, Edward C Keystone, Peter Nash
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the rheumatic diseases 80 (7) (2021)
Camille Roubille, Amandine Coffy, Nathalie Rincheval, Maxime Dougados, René-Marc Flipo, Jean-Pierre Daurès, Bernard G Combe
Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford, England) 60 (8) (2021)
Frank Behrens, Soyi Liu Leage, Christophe Sapin, Celine El Baou, Inmaculada De La Torre, Gabriella Meszaros, Larissa Valor-Méndez, Bernard G Combe, Filip E Van den Bosch, Laure Gossec
Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Clinical rheumatology 40 (12) (2021)
Bernard G Combe, Nathalie Rincheval, Francis Berenbaum, Patrick Boumier, Alain Cantagrel, Philippe Dieude, Maxime Dougados, Bruno Fautrel, René-Marc Flipo, Philippe Goupille, Xavier Mariette, Alain Saraux, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Jean-Pierre Daurès
Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford, England) 60 (11) (2021)
Sylvain Mathieu, Bruno Pereira, Alain Saraux, Christophe Richez, Bernard G Combe, Martin Soubrier
Disease-modifying drug retention rate according to patient age in patients with early rheumatoid arthritis: analysis of the ESPOIR cohort. Rheumatology international 41 (5) (2021)
Alain Saraux, René-Marc Flipo, Francis Fagnani, Jacques Massol, Gabrielle Cukierman, Jean-Michel Joubert, Philippe Huot-Marchand, Bernard G Combe
Early non-response to certolizumab pegol in rheumatoid arthritis predicts failure to achieve low disease activity at 1 year: data from a prospective observational study. RMD open 6 (1) (2021)
Bernard G Combe, Tsen-Fang Tsai, J Eugene Huffstutter, Aubrey Trevelin Sprabery, Chen-Yen Lin, So Young Park, Andris Kronbergs, Matthew M Hufford, Peter Nash
Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. Arthritis research & therapy 23 (1) (2021)
Bernard G Combe, Proton Rahman, Hideto Kameda, Juan D Cañete, Gaia Gallo, Noah Agada, Wen Xu, Mark C Genovese
Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis research & therapy 22 (1) (2020)
Christian Dejaco, Alessia Alunno, Johannes W J Bijlsma, Annelies Boonen, Bernard G Combe, Axel Finckh, Pedro M Machado, Ivan Padjen, Francisca Sivera, Tanja Alexandra Stamm, Frank Buttgereit
Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Annals of the rheumatic diseases (2020)
Roberto Felice Caporali, Yannick Allanore, Rieke E Alten, Bernard G Combe, Patrick Durez, Florenzo Iannone, Mike T Nurmohamed, Sang Joon Lee, Taek Sang Kwon, Jean Soo Choi, Gahee Park, Dae Hyun Yoo
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. Expert review of clinical immunology 17 (1) (2020)

Bernard G Combe.css-eqlu8i{font-size:small;padding-left:4px;} (B Combe, Bernard Combe)

Publication Activity (10 Years)

Top Topics

Top Venues

Bernard G Combe (B Combe, Bernard Combe)